Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 2/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 10/20 | 0.46 |
| ▸ | TGM2 | P21980 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6295429 | 0.93 | PTGS2 (0.52) | ENPP2PTGS2PTGS1 | |
| SCHEMBL2376239 | 0.85 | ENPP2 (0.72) | ENPP2PTGS2 | |
| SCHEMBL23145865 | 0.79 | ENPP2 (0.41) | ENPP2PTGS2 | |
| SCHEMBL2376235 | 0.78 | ENPP2 (0.56) | ENPP2PTGS2TGM2 | |
| SCHEMBL1751990 | 0.77 | ENPP2 (0.50) | ENPP2PTGS2TGM2 | |
| SCHEMBL16289366 | 0.77 | AKR1C3 (0.49) | ENPP2PTGS2 | |
| SCHEMBL10300269 | 0.77 | PTGS2 (0.62) | ENPP2PTGS2PTGS1 | |
| SCHEMBL17548700 | 0.77 | ENPP2 (0.62) | ENPP2PTGS2 | |
| SCHEMBL7677302 | 0.77 | PTGS2 (0.62) | ENPP2PTGS2PTGS1 | |
| SCHEMBL517832 | 0.74 | ENPP2 (0.59) | ENPP2PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 825 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230132298-A1 | OXABOROLE ESTERS AND USES THEREOF | ANACOR PHARMACEUTICALS, LLC | 2023-04-27 | — | — | US | claimed |
| CN-113620967-B | Alpha-mangostin derivative and preparation method and application thereof | 广州中医药大学(广州中医药研究院) | 2023-01-06 | — | — | CN | claimed |
| EP-3692101-B1 | BRILLIANT BLUE (BBG) DYE DERIVATIVES AND STAINING COMPOSITIONS COMPRISING THE SAME FOR SELECTIVELY STAINING BIOLOGICAL SUBSTRATES | ALFA INSTR S R L (IT) | 2022-01-12 | — | — | EP | claimed |
| CN-113620967-A | Alpha-mangostin derivative and preparation method and application thereof | 广州中医药大学(广州中医药研究院) | 2021-11-09 | — | — | CN | claimed |
| US-20210101916-A1 | OXABOROLE ESTERS AND USES THEREOF | ANACOR PHARMACEUTICALS, INC. | 2021-04-08 | — | — | US | claimed |
| WO-2021062089-A1 | XANTHINE CB1 INHIBITORS | GOLDFINCH BIO, INC. (US) | 2021-04-01 | — | — | WO | claimed |
| EP-3692101-A1 | BRILLIANT BLUE (BBG) DYE DERIVATIVES AND STAINING COMPOSITIONS COMPRISING THE SAME FOR SELECTIVELY STAINING BIOLOGICAL SUBSTRATES | Alfa Instruments S.r.l. (IT) | 2020-08-12 | — | — | EP | claimed |
| US-10435376-B2 | Derivatives of 1H-imidazole-4,5-dicarboxamide and use thereof in preparation of anticoccidial drugs | Guangzhou Insighter Biotechnology Co., Ltd. (CN) | 2019-10-08 | — | — | US | claimed |
| EP-3101017-B1 | 4'-O-SUBSTITUTED ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORP (US) | 2019-06-12 | — | — | EP | claimed |
| WO-2019068935-A1 | BRILLIANT BLUE (BBG) DYE DERIVATIVES AND STAINING COMPOSITIONS COMPRISING THE SAME FOR SELECTIVELY STAINING BIOLOGICAL SUBSTRATES | ALFA INSTRUMENTS S.R.L. (IT) | 2019-04-11 | — | — | WO | claimed |
| US-5998468-A | CARDIOVASCULAR DISORDERS; RESPIRATORY SYSTEM DISORDERS; ANTICANCER AGENTS | WARNER-LAMBERT COMPANY (US) | 1999-12-07 | — | — | US | claimed |
| US-5922759-A | Butenolide endothelin antagonists | WARNER-LAMBERT COMPANY (US) | 1999-07-13 | — | — | US | claimed |
| US-5691373-A | TREATING SUBARACHNOID HEMORRHAGE | WARNER-LAMBERT COMPANY (US) | 1997-11-25 | — | — | US | claimed |
| WO-1997037986-A1 | ENDOTHELIN ANTAGONISTS WITH ETHER-LINKED GROUPS | WARNER-LAMBERT COMPANY (US) | 1997-10-16 | — | — | WO | claimed |
| WO-1997008169-A1 | FURANONE ENDOTHELIN ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1997-03-06 | — | — | WO | claimed |
| WO-1997002265-A1 | BUTENOLIDE ENDOTHELIN ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1997-01-23 | — | — | WO | claimed |
| EP-0714391-A1 | SUBSTITUTED 2(5H)FURANONE, 2(5H)THIOPHENONE AND 2(5H)PYRROLONE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ENDOTHELIN ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1996-06-05 | — | — | EP | claimed |
| WO-1995005376-A1 | SUBSTITUTED 2(5H)FURANONE, 2(5H)THIOPHENONE AND 2(5H)PYRROLONE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ENDOTHELIN ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1995-02-23 | — | — | WO | claimed |
| EP-0011173-B1 | PROCESS FOR PRODUCING ANTIBIOTIC BETA-LACTAM COMPOUNDS | SANRAKU-OCEAN CO., LTD. (JP) | 1983-05-11 | — | — | EP | claimed |
| US-4337199-A | Antibiotic β-lactam compounds, production thereof, and their use as antimicrobial agent | SANRAKU-OCEAN CO., LTD. (JP) | 1982-06-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230132298-A1 | OXABOROLE ESTERS AND USES THEREOF | OXA1L, HSD17B12, OXER1 | ENPP2 394/4885PTGS2 3056/4885TGM2 1250/4885 |
| US-20210101916-A1 | OXABOROLE ESTERS AND USES THEREOF | OXA1L, HSD17B12, OXER1 | ENPP2 394/4885PTGS2 3056/4885TGM2 1250/4885 |
| US-10435376-B2 | Derivatives of 1H-imidazole-4,5-dicarboxamide and use thereof in preparation of anticoccidial drugs | CYP3A5, DDC, CPS1 | ENPP2 4260/4885PTGS2 1282/4885TGM2 2715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.